AU2003288898A1 - Antisense modulation of endothelial specific molecule 1 expression - Google Patents

Antisense modulation of endothelial specific molecule 1 expression

Info

Publication number
AU2003288898A1
AU2003288898A1 AU2003288898A AU2003288898A AU2003288898A1 AU 2003288898 A1 AU2003288898 A1 AU 2003288898A1 AU 2003288898 A AU2003288898 A AU 2003288898A AU 2003288898 A AU2003288898 A AU 2003288898A AU 2003288898 A1 AU2003288898 A1 AU 2003288898A1
Authority
AU
Australia
Prior art keywords
expression
specific molecule
antisense modulation
endothelial specific
endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003288898A
Other versions
AU2003288898A8 (en
Inventor
David W. Griggs
Edward J. Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2003288898A8 publication Critical patent/AU2003288898A8/en
Publication of AU2003288898A1 publication Critical patent/AU2003288898A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003288898A 2002-08-19 2003-08-19 Antisense modulation of endothelial specific molecule 1 expression Abandoned AU2003288898A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40449502P 2002-08-19 2002-08-19
US60/404,495 2002-08-19
PCT/US2003/025833 WO2004021978A2 (en) 2002-08-19 2003-08-19 Antisense modulation of endothelial specific molecule 1 expression

Publications (2)

Publication Number Publication Date
AU2003288898A8 AU2003288898A8 (en) 2004-03-29
AU2003288898A1 true AU2003288898A1 (en) 2004-03-29

Family

ID=31978255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003288898A Abandoned AU2003288898A1 (en) 2002-08-19 2003-08-19 Antisense modulation of endothelial specific molecule 1 expression

Country Status (4)

Country Link
EP (1) EP1543159A2 (en)
JP (1) JP2006511207A (en)
AU (1) AU2003288898A1 (en)
WO (1) WO2004021978A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
AU2006216514C1 (en) * 2005-02-25 2012-09-27 Isis Pharmaceuticals, Inc. Compositions and their uses directed to IL-4R alpha
EP2076600A1 (en) * 2006-10-18 2009-07-08 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
KR101058753B1 (en) * 2007-11-22 2011-08-24 한국생명공학연구원 Characterization of ESM-1 as a tumor associated marker of colorectal cancer
WO2014112144A1 (en) * 2013-01-15 2014-07-24 国立大学法人熊本大学 Nucleic acid anticancer agent targeting satellite noncoding rna derived from chromosome centromere, and method using anticancer agent
US20160025738A1 (en) * 2013-03-04 2016-01-28 Iq Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
NL2016967B1 (en) * 2016-06-15 2017-12-21 Iq Products B V Markers and their ratio to determine the risk for early-onset preeclampsia.
KR102612990B1 (en) * 2020-12-02 2023-12-13 주식회사 에이치피바이오 Rna aptamer specifically binding to esm-1 protein and using the same
CN115154605A (en) * 2022-05-31 2022-10-11 首都医科大学附属北京安贞医院 Use of products for reducing the level of endothelial cell specific molecule-1 in the preparation of products for treating vascular inflammation or atherosclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670328B1 (en) * 1997-06-24 2003-12-30 Institut Pasteur De Lille Proteins and peptides derived from protein ESM-1 and their uses in the treatment and diagnosis of diseases linked to leukocyte migration
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
US6436909B1 (en) * 1999-09-17 2002-08-20 Isis Pharmaceuticals, Inc. Antisense inhibition of transforming growth factor-β expression
US6475797B1 (en) * 2000-11-03 2002-11-05 Isis Pharmaceuticals, Inc. Antisense modulation of SR-CYP expression

Also Published As

Publication number Publication date
AU2003288898A8 (en) 2004-03-29
EP1543159A2 (en) 2005-06-22
JP2006511207A (en) 2006-04-06
WO2004021978A2 (en) 2004-03-18
WO2004021978A3 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
AU2003281327A1 (en) Antisense modulation of tfg-beta 2 expression
AU2002227435A1 (en) Antisense modulation of calreticulin expression
AU2003237875A1 (en) Antisense modulation of apolipoprotein b expression
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2002350228A1 (en) Antisense modulation of myd88 expression
AU2003268096A1 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU2002320525A1 (en) Antisense modulation of glioma-associated oncogene-2 expression
AU2002366788A1 (en) Antisense modulation of ship-1 expression
AU2003239579A1 (en) Antisense modulation of vegf-c expression
AU2003297553A1 (en) Modulation of huntingtin interacting protein 2 expression
AU2003288898A1 (en) Antisense modulation of endothelial specific molecule 1 expression
AU2002318139A1 (en) Antisense modulation of src-c expression
AU2002357102A1 (en) Antisense modulation of cd36l1 expression
AU2003257966A1 (en) Antisense modulation of lar expression
AU2003298619A1 (en) Modulation of huntingtin interacting protein 1 expression
AU2002322551A1 (en) Antisense modulation of rip2 expression
AU2001268322A1 (en) Antisense modulation of c/ebp alpha expression
AU2002349389A1 (en) Antisense modulation of activating transcription factor 3 expression
AU2002347809A1 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
AU2003237211A1 (en) Antisense modulation of vegf-b expression
AU2003241496A1 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU2003243589A1 (en) Antisense modulation of smrt expression
AU2003230301A1 (en) Antisense modulation of dyrk4 expression
AU2003236510A1 (en) Antisense modulation of ptpn12 expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase